Clinical and sociodemographic characteristics as predictors for quality of life in transmasculine and transfeminine individuals receiving gender-affirming hormone therapy

被引:1
|
作者
Lad, Saloni U. [1 ]
Sinopoli, Jacob [2 ,3 ]
Khong, Brian [4 ]
Conroy, Britt [3 ,5 ]
Perzynski, Adam T. [6 ]
del Rincon, Juan P. [7 ,8 ]
机构
[1] Cleveland Clin Lerner Coll Med, 9501 Euclid Ave, Cleveland Hts, OH 44195 USA
[2] Chester Summer Scholars Program, Metrohlth Med Syst, 2500 Metrohlth Dr, Cleveland Hts, OH 44109 USA
[3] Case Western Reserve Univ, Cleveland Hts, OH USA
[4] Dept Med, Metrohlth Syst, 2500 Metrohlth Dr, Cleveland Hts, OH 44109 USA
[5] Univ Hosp Cleveland Med Ctr, Dept Urol & Family Med & Community Hlth, 11100 Euclid Ave, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ Metrohlth, Ctr Healthcare Res & Policy, 10900 Euclid Ave, Cleveland, OH 44106 USA
[7] Metrohlth Syst, Dept Med, Cleveland, OH USA
[8] Cleveland Clin, Endocrinol & Metab Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
关键词
Transgender medicine; Social determinants of health; Quality of life; Gender -affirming hormone therapy; ELECTRONIC HEALTH RECORDS; ALCOHOL-CONSUMPTION; TRANSGENDER INDIVIDUALS; FINANCIAL STRAIN; MENTAL-HEALTH; AUDIT-C; RISK; STRESS; RECOMMENDATIONS; METABOLISM;
D O I
10.1016/j.socscimed.2024.116734
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Healthcare systems and providers have increasingly acknowledged the role and impact of social determinants in overall health. However, gender -diverse individuals face persistent health disparities due to their identities. There is limited research on the impact of clinical and sociodemographic characteristics on mood and quality of life (QoL) for transgender (TG) individuals. Our study aims to understand and better elucidate social and clinical characteristics of transmasculine (TM) and transfeminine (TF) individuals and their impact on quality of life and depressive symptoms. In this cross-sectional study, 298 TF and TM individuals on gender -affirming hormone therapy (GAHT) were surveyed about their demographic characteristics (age, gender identity, body mass index (BMI), and education), social needs, mood, and quality of life. Multivariable regression modelling was performed to assess the effect of each variable listed above on three domains of QoL (psychological, environmental, and physical) as well as depressive symptoms. We find that QoL scores are similar between TM and TF individuals, with scores in the psychological domain particularly low in both cohorts. TM individuals report higher rates of stress and restroom avoidance than TF individuals. In particular, psychological well-being (measured by the psychological domain of QoL and depressive symptoms) is significantly associated with increased BMI, financial instability, and stress in TM individuals while for TF individuals, psychological well-being is associated with stress and social integration. These data suggest that social circumstances are key drivers of QoL and psychological well-being among gender -diverse individuals receiving GAHT with specific differences between TF and TM individuals. This information may be utilized by healthcare providers and policymakers to address and improve clinical care and social policies to improve health equity for gender -diverse individuals.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The Utility of Preclinical Models in Understanding the Bone Health of Transgender Individuals Undergoing Gender-Affirming Hormone Therapy
    Varun S. Venkatesh
    Tian Nie
    Jeffrey D. Zajac
    Mathis Grossmann
    Rachel A. Davey
    Current Osteoporosis Reports, 2023, 21 : 825 - 841
  • [42] The Effect of Gender-Affirming Hormones on Gender Dysphoria, Quality of Life, and Psychological Functioning in Transgender Individuals: A Systematic Review
    van Leerdam, Taylah R.
    Zajac, Jeffrey D.
    Cheung, Ada S.
    TRANSGENDER HEALTH, 2023, 8 (01) : 6 - 21
  • [43] Cystatin C-Based eGFR Changes during Gender-Affirming Hormone Therapy in Transgender Individuals
    van Eeghen, Sarah A.
    Wiepjes, Chantal M.
    T'Sjoen, Guy
    Nokoff, Natalie J.
    den Heijer, Martin
    Bjornstad, Petter
    van Raalte, Daniel H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (12): : 1545 - 1554
  • [44] Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals
    Morgan, Kylie M.
    Deshler, Leah N.
    Tibbs, Michelle D.
    Qiao, Edmund M.
    Anger, Jennifer T.
    Salmasi, Amirali
    Marshall, Deborah C.
    Sanghvi, Parag
    Rose, Brent S.
    Riviere, Paul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (03): : 761 - 767
  • [45] Evaluating the Electrocardiographic Characteristics of Transgender Patients Undergoing Gender-Affirming Hormone Therapy With Artificial Intelligence
    Sang, Philip
    Adel, Fadi
    Maheshwari, Arvind
    Mangold, Kathryn
    Attia, Zachi
    Cummings, Paige
    Davidge-Pitts, Caroline
    Lopez-Jimenez, Francisco
    Friedman, Paul
    Noseworthy, Peter A.
    Mankad, Rekha
    CIRCULATION, 2022, 146
  • [46] The Utility of Preclinical Models in Understanding the Bone Health of Transgender Individuals Undergoing Gender-Affirming Hormone Therapy
    Venkatesh, Varun S.
    Nie, Tian
    Zajac, Jeffrey D.
    Grossmann, Mathis
    Davey, Rachel A.
    CURRENT OSTEOPOROSIS REPORTS, 2023, 21 (06) : 825 - 841
  • [47] Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review
    Spanos, Cassandra
    Bretherton, Ingrid
    Zajac, Jeffrey D.
    Cheung, Ada S.
    WORLD JOURNAL OF DIABETES, 2020, 11 (03) : 66 - 77
  • [48] Transgender and Nonbinary Individuals' Perceptions Regarding Gender-Affirming Hormone Therapy and Cardiovascular Health: A Qualitative Study
    Rytz, Chantal L.
    Pattar, Badal S. B.
    Mizen, Sara J.
    Lieb, Parker
    Parsons Leigh, Jeanna
    Saad, Nathalie
    Dumanski, Sandra M.
    Beach, Lauren B.
    Marshall, Zack
    Newbert, Amelia M.
    Peace, Lindsay
    Ahmed, Sofia B.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2024, 17 (09):
  • [49] Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review
    McFarlane, Thomas
    Zajac, Jeffrey D.
    Cheung, Ada S.
    CLINICAL ENDOCRINOLOGY, 2018, 89 (06) : 700 - 711
  • [50] The Impact of Gender-Affirming Cross-Sex Hormone Therapy on Primary Headaches in Transgender and Gender Diverse (TGD) Individuals
    Sim, Danielle
    Hassan, Bashar
    Krishna, Samarth
    Bejo, Sarah
    Martheswaran, Tanisha
    Han, Yunah
    Liang, Fan
    Johnson, Emily
    ANNALS OF NEUROLOGY, 2024, 96 : S214 - S214